- 78% achieved EASI 75 improvement by week 24.
- 54% achieved clear to almost clear skin (IGA 0/1).
- 58% of patients reported significant itch reduction.
- Safety profile remained manageable with no serious adverse events.
- Limitations include open-label design and short duration.
Lebrikizumab 24-Week Trial in Skin of Color Atopic Dermatitis
Conexiant
September 16, 2025
